

- **Full Name:** Sehhoon Park
 - **Current Position & Affiliation:** Assistant Professor, Samsung Medical Center
 - **Country:** Republic of Korea
-

• Educational Background:

- Mar. 2001- Feb. 2003 Kyungbook-Science High school, Pohang, Korea
- Mar. 2003- Feb. 2005 Premedical School, Seoul National University, Seoul, Korea
- Mar. 2005- Feb. 2009 Seoul National University College of Medicine, Seoul, Korea
- Mar. 2014- Feb, 2016 Master of Science, Department in Clinical Medical Science, Seoul National University College of Medicine, Seoul, Korea
- Mar. 2018- Aug, 2020 PhD. Degree, Graduate School of Medicine, Sungkyunkwan University, Seoul, Korea

• Professional Experience:

- Mar. 2011- Feb. 2012 Internship, Seoul National University Hospital, Seoul, Korea
- Mar. 2012- Feb. 2016 Residency Course at Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Jun. 2016- Nov. 2017 Country Medical Lead, Medical Affairs, Roche Korea
- Dec. 2017- Nov. 2019 Clinical Fellow, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea.
- Dec. 2019- Feb. 2021 Clinical assistant professor, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea.
- Mar. 2022- Current Assistant professor, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea.

• Professional Organizations:

- Feb. 2012- Present Korean Association of Internal Medicine, Member
- Mar. 2014- Present Korean Cancer Association, Member
- Mar. 2014- Present Korean Association for Clinical Oncology, Member
- Mar. 2014- Present American Society of Clinical Oncology, Member
- Dec. 2014- Present American Association for Cancer Research, Member

• Main Scientific Publications:

1. Park S, Ock C-Y, Kim H, et al: Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer. *Journal of Clinical Oncology:JCO*. 21.02010, 2022
2. Park S, Lee M-H, Seong M, et al: A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. *Annals of Oncology* 31:1397-1404, 2020